Edgewise Therapeutics (EWTX) Non-Current Assets (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Non-Current Assets of $8.7 million for Q1 2026, down 5.29% sequentially from $9.2 million in Q4 2025, and down 22.14% YoY from $11.2 million in Q1 2025.
Edgewise Therapeutics (EWTX) Non-Current Assets (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $8.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 22.14% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.6 million (down 19.33% YoY) and the FY2025 annual result came in at $9.2 million, down 18.67% from the prior year.
- Non-Current Assets declined to $8.7 million in Q1 2026 per EWTX's latest filing, from $9.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $13.6 million in Q2 2023 and troughed at $4.1 million in Q2 2022.
- A 5-year average of $10.3 million and a median of $11.2 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 674.05% in 2022, then declined 22.14% in 2026.
- Over 5 years, Non-Current Assets stood at $10.1 million in 2022, then climbed by 29.06% to $13.0 million in 2023, then retreated by 13.07% to $11.3 million in 2024, then fell by 18.67% to $9.2 million in 2025, then declined by 5.29% to $8.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $8.7 million, $9.2 million, and $9.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 8.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.17 Mn |
| Mar 31, 2026 | 8.73 Mn |
| Dec 31, 2025 | 9.22 Mn |
| Sep 30, 2025 | 9.57 Mn |
| Jun 30, 2025 | 10.08 Mn |
| Mar 31, 2025 | 11.21 Mn |
| Dec 31, 2024 | 11.33 Mn |
| Sep 30, 2024 | 11.85 Mn |
| Jun 30, 2024 | 12.21 Mn |
| Mar 31, 2024 | 12.38 Mn |
| Dec 31, 2023 | 13.04 Mn |
| Sep 30, 2023 | 13.44 Mn |
| Jun 30, 2023 | 13.63 Mn |
| Mar 31, 2023 | 13.04 Mn |
| Dec 31, 2022 | 10.10 Mn |
| Sep 30, 2022 | 7.01 Mn |
| Jun 30, 2022 | 4.06 Mn |
| Mar 31, 2022 | 4.13 Mn |
| Dec 31, 2021 | 1.46 Mn |
| Sep 30, 2021 | 1.21 Mn |